Physician profile
Michael Boes
NPI 1922621754
$1,566.01
in general payments reported to CMS, 2019-2025
12 companies · $443 in 2025
The $443 reported for 2025 was more than what 77% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $380 · 2023: $329 · 2024: $414 · 2025: $443.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,186.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,185.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $333.36 | 2022-2024 | Mavenclad, Mavenclad |
| Ucb, INC. | $193.75 | 2024-2025 | Rystiggo, Fintepla, Briviact |
| Alexion Pharmaceuticals, INC. | $171.61 | 2023 | Ultomiris |
| Astrazeneca Pharmaceuticals LP | $143.70 | 2022 | |
| Neurelis, INC. | $135.17 | 2024-2025 | Valtoco |
| Tg Therapeutics, INC. | $125.53 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $122.79 | 2022 | |
| Argenx US, INC. | $100.94 | 2024-2025 | Vyvgart Hytrulo |
| Abbvie INC. | $90.20 | 2023 | Qulipta, Ubrelvy |
| Genentech USA, INC. | $66.05 | 2024-2025 | Ocrevus Zunovo, Ocrevus |
| Tanabe Pharma America, INC. | $53.14 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $29.77 | 2025 | Zeposia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Boes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.